High Tide’s NCCC Initiative: Navigating Cannabis Policy Trends in Search

High Tide's Strategic Move: Joining the National Compassionate Care Council

High Tide made a calculated announcement on March 4, 2026, revealing its role as a founding member of the newly established National Compassionate Care Council (NCCC). This move was far from subtle—it was a deliberate effort to capture attention amid a significant shift in cannabis policy. The backdrop for this development was President Trump’s December 2025 executive order on cannabis rescheduling, which has sparked renewed momentum and debate within the industry.

The NCCC was created as a direct answer to this executive order, aiming to serve as a unified advocate for medical cannabis policy in Washington. For High Tide, joining the council is a chance to align with a hot policy topic and spotlight its U.S.-based, hemp-derived CBD subsidiaries as influential voices in the evolving cannabinoid therapy landscape. The company’s CEO described this step as participating in a “meaningful transition” for federal cannabis regulation.

However, the market’s response was lukewarm. On the day of the announcement, High Tide’s shares dipped by 1.2% to close at $2.47, showing little enthusiasm. The stock remains close to its 52-week low of $1.64, reflecting persistent skepticism toward cannabis equities. This scenario is familiar: a company enters a trending policy discussion, but investors remain unconvinced. The real question is whether this council membership will become a pivotal chapter in High Tide’s story or simply a minor detail amid broader financial challenges.

Market Trends: Policy Cycles and Investor Focus

Investor and media attention is currently fixated on cannabis policy developments. Early 2026 has seen a spike in searches for terms like “cannabis rescheduling” and “marijuana policy,” fueled by the ongoing process initiated by the December executive order. This policy cycle has become a focal point for financial news, driving the narrative and shaping market sentiment.

Sample Trading Strategy: HITI Absolute Momentum Long-Only

• Entry Criteria: Buy when the 252-day rate of change is positive and the closing price is above the 200-day simple moving average (SMA).
• Exit Criteria: Sell if the price drops below the 200-day SMA, after 20 trading days, or if a take-profit of +8% or stop-loss of −4% is reached.
• Asset: HITI
• Risk Controls:
  • Take-Profit: 8%
  • Stop-Loss: 4%
  • Maximum Hold: 20 days

Backtest Results

• Total Return: 14.8%
• Annualized Return: 8%
• Maximum Drawdown: 10.04%
• Profit-Loss Ratio: 2.4

Trade Performance Metrics

• Total Trades: 13
• Winning Trades: 5
• Losing Trades: 8
• Win Rate: 38.46%
• Average Hold Period: 12.15 days
• Max Consecutive Losses: 2
• Average Gain per Win: 8.4%
• Average Loss per Loss: 3.23%
• Largest Single Gain: 12.92%
• Largest Single Loss: 4.31%

Policy Divergence: Marijuana Rescheduling vs. Hemp Contraction

The current policy landscape is marked by a stark contrast. While there is momentum to move marijuana to Schedule III, hemp is facing the threat of stricter federal oversight. Analysts describe this as a “split-screen” scenario for 2026: marijuana policy is becoming more permissive, but hemp businesses are bracing for a regulatory squeeze. This duality introduces both risks and opportunities, with investors closely monitoring real progress on rescheduling rather than organizational affiliations.

Strategic Positioning: High Tide’s Path Forward

High Tide is banking on its U.S. CBD operations to drive growth. The 2021 acquisition of NuLeaf Naturals was a pivotal move, bringing in a company with a robust financial track record—71% gross margins and 25% adjusted EBITDA margins in 2020. This operational strength is the true asset, not simply the NCCC membership. The challenge is whether this business can adapt to a maturing market and increasingly complex regulations.

The CBD sector has moved beyond its initial hype. According to industry analysis, it is transitioning into a phase of maturity and sophistication. Brands must now innovate to avoid becoming generic. Success will depend on developing advanced products, such as minor cannabinoids and functional blends, rather than relying on basic CBD oils. NuLeaf’s established platform and cGMP certification offer a competitive advantage, but sustained innovation is essential to maintain its premium status.

The main obstacle is regulatory uncertainty, which policy changes alone may not resolve. As federal policy enters 2026 in a “split-screen” mode, marijuana rescheduling advances while hemp faces tighter restrictions. This creates significant compliance risks for CBD companies. The same regulatory ambiguity that drives interest in policy news also threatens the stability of the CBD market. High Tide’s U.S. operations are thus navigating between the potential benefits of policy reform and the dangers of regulatory tightening.

Ultimately, joining the NCCC is a strategic positioning move, not a comprehensive solution. While it aligns High Tide with the cannabis policy conversation, the real test is whether NuLeaf can continue to innovate and thrive in a challenging market environment. For now, the policy wave is on the horizon, but the immediate challenges are compliance and competition.

Key Catalysts and Risks: What Investors Should Monitor

High Tide’s investment outlook depends on two critical factors: progress in cannabis policy and effective business execution. The NCCC membership sets the stage, but it is not the endgame. Here are the main points to watch:

• Policy Milestones: Track tangible developments in the U.S. cannabis rescheduling process. The December executive order was a starting point, but the decisive moment will be the DEA’s final rule. As noted in industry analysis, the process is ongoing and must follow administrative procedures before any changes take effect. Key indicators include the publication of the final rule and a solid administrative record. Moving cannabis to Schedule III would recognize its medical use federally and eliminate IRS 280E tax burdens, potentially opening new markets for High Tide’s U.S. brands.
• NuLeaf’s Innovation: The CBD market is rapidly evolving, and brands must stand out or risk being commoditized. The future lies in developing advanced products like minor cannabinoids (CBN, CBG) and functional blends. High Tide’s cGMP-certified operations provide a foundation, but the company must demonstrate its ability to move beyond basic offerings and build lasting brand loyalty.

The primary risk is that the NCCC membership could be seen as a distraction rather than a driver of value. While policy changes may be on the horizon, immediate regulatory pressures are intensifying. With federal policy in a “split-screen” state—marijuana policy advancing and hemp facing contraction—CBD businesses face a compliance cliff. If NuLeaf fails to innovate or the regulatory environment becomes too restrictive, the NCCC platform may offer little real benefit. For the investment thesis to hold, both policy momentum and strong execution are required; lacking either could lead to disappointment.